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Complete loss of gene function in humans by naturally
occurring biallelic loss-of-function mutations (human
knockout) is not a new concept. However, the recent
identification of human knockouts along the entire
spectrum of health and disease by next-generation
sequencing promises to unlock their full potential to
accelerate the medical and functional annotation of
the human genome.malformation) have astonishingly different phenotypesNext-generation sequencing of nucleic acids has done
more than amplify the throughput of sequencing by or-
ders of magnitude; it has eliminated a bottleneck that
shaped the way in which human genetics and, more
specifically, medical genetics was practiced. Free of the
constraint of having to develop a hypothesis to obtain
relevant sequence information, human geneticists are
now reveling in the flood of sequence data that is avail-
able to them with no prerequisites other than sample
availability. The implications of this paradigm shift are
far reaching and have yet to be fully captured. One such
implication is the rapidly growing trend of genotype-to-
phenotype approaches in which hypotheses about the
phenotype are generated after analyzing the sequence
data rather than before. No class of variants lends itself
to this new approach more readily than loss-of-function
(LOF) variants, which ‘knock out’ the involved gene such
that their biallelic presence essentially makes the individ-
ual into a human knockout for that gene. If there are
pathological consequences to loss of a gene’s function,
human knockouts for that gene offer the best opportun-
ity to study such consequences.Correspondence: FAlKuraya@kfshrc.edu.sa
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The clinical consequences of mutations in established
disease genes usually depend on the disease’s molecular
pathogenesis (dominant negative, dominant gain of func-
tion, loss of function, and so on) but even then, the
results of complete knockouts can be highly surprising.
For example, BRCA2 and APC are well established dom-
inant disease genes for breast/ovarian cancer and colon
cancer, respectively. However, human knockouts for
BRCA2 (primordial dwarfism) and APC (severe limb
from those of the established dominant phenotype in
haploinsufficient individuals [1, 2]. Even for known re-
cessive disease genes, human knockouts can have a dra-
matic phenotype that bears little or no resemblance to
the well established recessive disease; for example, the
NEB gene, which encodes a large cytoskeletal protein,
causes embryonic lethality in human knockouts, whereas
in those with less severe biallelic mutations it only
causes myopathy [3]. On the other hand, healthy people
who have knockouts in genes previously thought to
cause disease in a recessive manner can raise doubts
about the originally proposed disease links [4]. One par-
ticularly exciting potential of human knockouts is to un-
mask the true disease potential of genes that have
previously only been associated with rather than linked
to human disease. For example, DNASE1L3 is associated
with systemic lupus erythematosus, a complex multifac-
torial disorder, but its complete knockout directly causes
this disease in a Mendelian recessive manner [5]. Human
knockout events in known disease genes can also serve
as a bridge between Mendelian and complex phenotypes
in other ways. For example, we now know from large-
scale sequencing projects that knockout events in genes
known to exert Mendelian phenotypes related to glucose
and lipid homeostasis also have an important role in the
well known risk variation between individuals for dia-
betes mellitus and cardiovascular disease [5–7].s is an Open Access article distributed under the terms of the Creative Commons
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Traditionally, the identification of a human knockout for a
novel gene represented compelling evidence for establishing
novel disease-gene links. Such causal links were derived in
the context of a positional mapping strategy that attaches a
compelling probabilistic value to the locus. However, recent
studies have unveiled a previously unrecognized level of hu-
man knockout events. MacArthur et al. [8] found that
healthy people on average have about 15 complete knock-
out events (not counting splicing mutations that may or
may not lead to complete knockout) [8]. In the highly con-
sanguineous Saudi Arabian population, we found that in
the offspring of first cousin parents there were on average
23 complete knockout events, and this larger number was
mainly driven by the high percentage of autozygosity (iden-
tity by descent) [4]. Similarly, the recent study by Stefans-
son and colleagues showed that the Icelandic population,
with its strong founder effect, has a large burden of
complete knockout events [9]. These studies clearly show
that a knockout event in a novel gene does not necessarily
mean that this gene causes an individual’s phenotype. More
importantly, these studies truly usher in an era of genotype-
to-phenotype approaches with all the exciting possibilities
that follow.
Reverse phenotyping from large-scale human
knockout studies
Cohorts sequenced to date in search of human knock-
outs have given different estimates of the number of
knockout events per person depending on whether they
were enriched for complete (biallelic) knockout events.
The study by Stefansson and colleagues [9] is particu-
larly noteworthy not only because of the size of the se-
quenced cohort (2,636) or its enrichment for biallelic
knockout events (due to the founder effect of the Ice-
landic population) but also because the LOF alleles were
imputed by high-density genotyping such that the cohort
size screened for these events was effectively increased
to >100,000 [9]. This is by far the largest study to date
on human knockouts and provides a valuable resource
in the discovery of the role of complete human knock-
outs in general populations. Although the study was per-
formed on a genetic isolate, some of its results seem to
be generalizable; for example, the predilection of knock-
out events to affect olfactory genes was similarly ob-
served by MacArthur et al. [8] and Alsalem et al. [4]. As
the study cohort was mixed, their impressive list of
about 5,000 genes with biallelic LOF [9] should not be
interpreted as a list of genes that do not cause severe
Mendelian diseases in humans. For instance, they pro-
posed that their knockout subjects for LRIG3 and
OTOP1 are candidates for auditory evaluation to assess
for hearing loss given the established role for these genesin ear development [9]. On the other hand, the cohorts
studied by MacArthur et al. [8] and Alsalem et al. [4]
were selected such that severe Mendelian diseases (or
their casual variants) were excluded. The resulting par-
tially overlapping lists of 221 and 169 genes, respectively
(the former excluding splicing variants), were therefore
significantly depleted for severe Mendelian phenotypes.
Consequently, these knockout events represent a rich re-
source to generate hypotheses about the apparent toler-
ance of the human genome to these knockout events.
One of the most intriguing, testable hypotheses is that
this tolerance is context dependent. The context could be
genetic or environmental. For example, there are numer-
ous single knockouts in model organisms that appear
completely normal but a phenotype is observed in double
knockouts [5]. A second knockout event is not necessary,
however, because milder genetic modifiers (referred to as
genetic background in mouse models) can also be import-
ant in determining the phenotypic expression of the
human knockout events as they do in knockout animal
models. Environmental factors may also be important
determinants; for example, FUT2 knockout may lead to
clinically consequential B12 deficiency only in nutrition-
deficiency states [4]. We have also observed knockout
events in several immune-related genes and it is possible
that these will only manifest phenotypically under certain
microbial exposures [4]. Knockout events may have a role
in human phenotypic diversity in less subtle ways [5]. For
example, knockout of olfactory and keratin genes may in-
fluence flavor preferences and hair texture, respectively.
These are just two of the many phenotypes that are not
typically assessed upon enrolling ‘healthy’ individuals in
these sequencing studies, so it is inevitable that reverse
phenotyping will become commonplace as we move from
the discovery of knockout events in genes to evaluating
their potential phenotypic consequences, taking a lead
from their known or predicted biological roles [5].
A field in its infancy
Human knockout research has already demonstrated a
great potential despite being in its very early stages.
What is clear is that large-scale sequencing studies from
cohorts enriched for autozygosity will provide the
necessary statistical power to capture viable human
knockout events. When such large datasets are avail-
able, interesting questions can be asked and answered in
terms of what a particular gene knockout event can
cause and in what context. PCSK9, knockouts of which
protect individuals from cholesterol-driven cardiovascu-
lar diseases, has become the poster child for the im-
mense pharmaceutical potential of human knockout
research. Drugs that block PCSK9 (mimicking the nat-
urally occurring human knockouts) are among the most
promising lipid lowering agents ever since statin class
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the cardiovascular benefits enjoyed by humans who have a
knockout of this gene [5]. It is inevitable that such re-
search will uncover knockouts that could be tapped for
similarly successful therapeutic opportunities [5]. The ap-
preciation of the influence of knockout events on the indi-
vidual risk for complex diseases is also very likely to see
significant growth in the near future [10, 11].
The stereotype of human knockouts as individuals with
esoteric severe diseases will quickly become a thing of the
past. Human geneticists are now bracing themselves for
human knockouts to be very much part of the genetic in-
dividuality that drives personalized medicine, and it is ex-
pected that the wider medical community will follow.
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